Insulet (NASDAQ:PODD) Price Target Raised to $370.00

Insulet (NASDAQ:PODD) had its price objective upped by Royal Bank Of Canada from $365.00 to $370.00 in a research note released on Friday morning,Benzinga reports. The brokerage currently has an outperform rating on the medical instruments supplier’s stock.

Several other research firms have also commented on PODD. Leerink Partners raised their price target on Insulet from $355.00 to $385.00 and gave the stock an “outperform” rating in a research report on Friday. Raymond James Financial increased their target price on Insulet from $360.00 to $366.00 and gave the stock an “outperform” rating in a research note on Friday. BTIG Research reissued a “buy” rating and set a $370.00 price target on shares of Insulet in a research report on Thursday. JPMorgan Chase & Co. lifted their price objective on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a report on Friday, September 12th. Finally, UBS Group raised their price target on shares of Insulet from $320.00 to $355.00 and gave the company a “neutral” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $371.38.

Insulet Trading Up 0.2%

PODD traded up $0.53 on Friday, hitting $320.35. The company had a trading volume of 544,810 shares, compared to its average volume of 719,407. The company’s fifty day moving average price is $325.06 and its 200 day moving average price is $310.30. Insulet has a 1 year low of $230.05 and a 1 year high of $353.50. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. The firm has a market cap of $22.55 billion, a P/E ratio of 97.37, a PEG ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, beating analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million during the quarter, compared to analysts’ expectations of $678.70 million. During the same period last year, the business earned $1.08 earnings per share. The business’s revenue for the quarter was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, equities analysts expect that Insulet will post 3.92 earnings per share for the current year.

Insider Transactions at Insulet

In related news, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This trade represents a 16.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Laetitia Cousin sold 797 shares of Insulet stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. This trade represents a 17.00% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Insulet

Hedge funds have recently made changes to their positions in the business. True Wealth Design LLC increased its position in Insulet by 288.0% in the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 72 shares during the period. Zions Bancorporation National Association UT purchased a new position in Insulet in the 1st quarter valued at $26,000. Larson Financial Group LLC increased its stake in Insulet by 426.3% in the 1st quarter. Larson Financial Group LLC now owns 100 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 81 shares during the period. Golden State Wealth Management LLC lifted its stake in shares of Insulet by 202.9% in the 2nd quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 69 shares during the period. Finally, SouthState Corp boosted its holdings in shares of Insulet by 253.3% in the first quarter. SouthState Corp now owns 106 shares of the medical instruments supplier’s stock valued at $28,000 after acquiring an additional 76 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.